172 related articles for article (PubMed ID: 19190121)
1. Notch1 mediates growth suppression of papillary and follicular thyroid cancer cells by histone deacetylase inhibitors.
Xiao X; Ning L; Chen H
Mol Cancer Ther; 2009 Feb; 8(2):350-6. PubMed ID: 19190121
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with histone deacetylase inhibitors and lithium chloride: a novel treatment for carcinoid tumors.
Adler JT; Hottinger DG; Kunnimalaiyaan M; Chen H
Ann Surg Oncol; 2009 Feb; 16(2):481-6. PubMed ID: 19030935
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors upregulate Notch-1 and inhibit growth in pheochromocytoma cells.
Adler JT; Hottinger DG; Kunnimalaiyaan M; Chen H
Surgery; 2008 Dec; 144(6):956-61; discussion 961-2. PubMed ID: 19041003
[TBL] [Abstract][Full Text] [Related]
4. Suberoyl bishydroxamic acid activates notch1 signaling and suppresses tumor progression in an animal model of medullary thyroid carcinoma.
Ning L; Jaskula-Sztul R; Kunnimalaiyaan M; Chen H
Ann Surg Oncol; 2008 Sep; 15(9):2600-5. PubMed ID: 18563491
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of growth in medullary thyroid cancer cells with histone deacetylase inhibitors and lithium chloride.
Adler JT; Hottinger DG; Kunnimalaiyaan M; Chen H
J Surg Res; 2010 Apr; 159(2):640-4. PubMed ID: 19394967
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells.
Condorelli F; Gnemmi I; Vallario A; Genazzani AA; Canonico PL
Br J Pharmacol; 2008 Feb; 153(4):657-68. PubMed ID: 18059320
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors upregulate Rap1GAP and inhibit Rap activity in thyroid tumor cells.
Dong X; Korch C; Meinkoth JL
Endocr Relat Cancer; 2011 Jun; 18(3):301-10. PubMed ID: 21367844
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells.
Takai N; Desmond JC; Kumagai T; Gui D; Said JW; Whittaker S; Miyakawa I; Koeffler HP
Clin Cancer Res; 2004 Feb; 10(3):1141-9. PubMed ID: 14871994
[TBL] [Abstract][Full Text] [Related]
9. Valproic acid inhibits growth, induces apoptosis, and modulates apoptosis-regulatory and differentiation gene expression in human thyroid cancer cells.
Shen WT; Wong TS; Chung WY; Wong MG; Kebebew E; Duh QY; Clark OH
Surgery; 2005 Dec; 138(6):979-84; discussion 984-5. PubMed ID: 16360381
[TBL] [Abstract][Full Text] [Related]
10. Suberoyl bishydroxamic acid inhibits cellular proliferation by inducing cell cycle arrest in carcinoid cancer cells.
Greenblatt DY; Cayo M; Ning L; Jaskula-Sztul R; Haymart M; Kunnimalaiyaan M; Chen H
J Gastrointest Surg; 2007 Nov; 11(11):1515-20; discussion 1520. PubMed ID: 17874277
[TBL] [Abstract][Full Text] [Related]
11. Suberoyl bis-hydroxamic acid activates Notch1 signaling and induces apoptosis in anaplastic thyroid carcinoma through p53.
Li J; Zheng X; Gao M; Zhao J; Li Y; Meng X; Qian B; Li J
Oncol Rep; 2017 Jan; 37(1):458-464. PubMed ID: 28004113
[TBL] [Abstract][Full Text] [Related]
12. Valproic acid induces Notch1 signaling in small cell lung cancer cells.
Platta CS; Greenblatt DY; Kunnimalaiyaan M; Chen H
J Surg Res; 2008 Jul; 148(1):31-7. PubMed ID: 18570928
[TBL] [Abstract][Full Text] [Related]
13. High doses of hydroxytyrosol induce apoptosis in papillary and follicular thyroid cancer cells.
Toteda G; Lupinacci S; Vizza D; Bonofiglio R; Perri E; Bonofiglio M; Lofaro D; La Russa A; Leone F; Gigliotti P; Cifarelli RA; Perri A
J Endocrinol Invest; 2017 Feb; 40(2):153-162. PubMed ID: 27592355
[TBL] [Abstract][Full Text] [Related]
14. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.
Rocchi P; Tonelli R; Camerin C; Purgato S; Fronza R; Bianucci F; Guerra F; Pession A; Ferreri AM
Oncol Rep; 2005 Jun; 13(6):1139-44. PubMed ID: 15870934
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors trichostatin A and valproic acid induce cell cycle arrest and p21 expression in immortalized human endometrial stromal cells.
Wu Y; Guo SW
Eur J Obstet Gynecol Reprod Biol; 2008 Apr; 137(2):198-203. PubMed ID: 17376583
[TBL] [Abstract][Full Text] [Related]
16. A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer.
Lin SF; Lin JD; Hsueh C; Chou TC; Wong RJ
PLoS One; 2017; 12(2):e0172315. PubMed ID: 28207834
[TBL] [Abstract][Full Text] [Related]
17. Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells.
Catalano MG; Fortunati N; Pugliese M; Costantino L; Poli R; Bosco O; Boccuzzi G
J Clin Endocrinol Metab; 2005 Mar; 90(3):1383-9. PubMed ID: 15585556
[TBL] [Abstract][Full Text] [Related]
18. Notch1 signaling is irresponsible to the anti-leukemic effect of HDACis in B-ALL Nalm-6 cells.
Shao N; Ma D; Wang J; Lu T; Guo Y; Ji C
Ann Hematol; 2013 Jan; 92(1):33-9. PubMed ID: 22968660
[TBL] [Abstract][Full Text] [Related]
19. Novel histone deacetylase inhibitors in the treatment of thyroid cancer.
Mitsiades CS; Poulaki V; McMullan C; Negri J; Fanourakis G; Goudopoulou A; Richon VM; Marks PA; Mitsiades N
Clin Cancer Res; 2005 May; 11(10):3958-65. PubMed ID: 15897598
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines.
Sakajiri S; Kumagai T; Kawamata N; Saitoh T; Said JW; Koeffler HP
Exp Hematol; 2005 Jan; 33(1):53-61. PubMed ID: 15661398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
